StockWatch
·

Desco Infratech Ltd Q2 FY27 Results

DESCOQ2 FY27 Results
Filing
DESCO INFRATECH · Q2 FY27 · THE VERDICT

78% Growth Delivered, But Profit Quality Deteriorated

Desco's H1 revenue surged 78.5% to ₹75 Cr, beating prior guidance. Yet EBITDA margins fell 193 basis points and PAT margins 202 bps YoY. Management's explanation — a shift toward lower-margin segments and execution overhead — rings hollow against the FY30 ₹1,000 Cr ambition.

09 Nov 2026 · 6 min read

On the surface, Desco delivered a clean beat: H1 revenue of ₹75 Cr far exceeded the implied run-rate from prior guidance, earnings per share jumped 54% to ₹12.38, and the executable order book of ₹384 Cr provides credible visibility to FY27 guidance of ₹190–200 Cr. But beneath that headline lies a profitability story that the market has already punished. EBITDA margin compressed 193 basis points and PAT margin fell 202 basis points year-on-year, even as the top line surged. Management attributes this to a mix shift — city gas distribution has expanded to 66% of revenue but at lower margins than the legacy mix — and execution overhead on infrastructure projects. That explanation is honest. It is also a warning.

Revenue H1 FY27

₹75 Cr

vs ₹42 Cr prior year

EBITDA margin

19.45%

−193 bps YoY to 19.45%

PAT margin

12.66%

−202 bps YoY

Order book

₹384 Cr

at various execution stages

The growth-quality paradox

Desco's reported PAT of ₹9.5 Cr rose 54% YoY, but the profit was not driven by operational leverage or margin expansion — the reverse. The company grew revenues faster than profit, a classic sign of execution drag. Breaking down the quarter: city gas distribution posted ₹49.67 Cr in revenue (66% of the total), up from ₹10.15 Cr in the prior-year H1. Segment results were ₹10.15 Cr, implying a blended margin of roughly 20%, well below the historical 24%+ the company has guided on legacy CGD work. General construction (piling, infrastructure) added ₹21.47 Cr at a ~16% margin. Power distribution, still nascent at ₹3.89 Cr, barely broke even. Compressed biogas, the company's new venture, posted a loss of ₹5.09 lakh in H1.

Management's pitch is that this is a temporary squeeze — that as execution overhead stabilizes and the new ventures (especially compressed biogas) scale, margins will recover toward the segment-wise targets of 12.5–13.5% for CGD (ex-delivery), ~10–11% for solar EPC, and 11–12% for power. Those targets, announced for the first time on this call, are lower than prior-year consolidated margins. That is a reset. The company is signaling that even with better execution, normalized margins in the near term will be in the high-teens, not the low-20s investors recall from the pre-infrastructure shift era.

Management's claims vs. what holds up

  • Strong order book to sustain growth trajectory

  • Margins maintained despite growth

  • Compressed biogas venture commercialization imminent

  • Diversification into power, solar, green hydrogen reduces CGD concentration

The order book claim is rock solid. ₹384 Cr of executable work at various stages, with a ₹740+ Cr tender pipeline, provides genuine visibility through FY28. H1 delivered 78.5% growth on the prior 70–80% conservative guidance, proving execution discipline. That check passes. On margins, the company explicitly contradicted itself: prior calls implied sustainability near 21%; this call introduced segment-wise guidance in the high-teens and low-20s. Margins were not maintained; they were repriced downward. The compressed biogas claim also holds: the pilot is complete, 97–98% capacity has been incurred, and injection into the Adani Total Gas pipeline is expected before Diwali 2026. But diversification reducing CGD concentration is overstated. At 66% of H1 revenue, city gas distribution is still the core, and early-stage ventures account for <₹5 Cr in losses and gains combined. True diversification is 2–3 years away, if execution holds.

What changed on this call

Segment-wise margin guidance quantified for the first time. Prior calls sidestepped granular targets; this call nailed them: CGD 12.5–13.5%, solar EPC ~10–11%, power 11–12%. This is not a positive surprise; it is a reset toward lower normalized expectations.

Working capital management elevated to a board-level priority. The company explicitly acknowledged that current assets have ballooned (due to government project certifications and cash collection delays) and committed to a 45–60 day conversion cycle. Prior calls emphasized revenue; this call tied profitability to cash generation. That shift reflects investor pressure and real execution friction.

Senior management strengthened for long-term ambition. Recent hires (Arun Kumar for execution excellence, Shailesh Naik as Independent Director, Kalpesh Patel) signal a governance upgrade aimed at the FY30 ₹1,000 Cr target. But hiring does not de-risk execution; it signals the company felt it was under-resourced.

UAE Desco Global FZ-LLC remains on hold. Geopolitical tensions in the Middle East have deferred international expansion indefinitely. The company is participating in ADNOC tenders and hopes to open a price bid for Ras Al Khaimah within 2–3 months, but no timeline is firm. This is a strategic setback for a company that had positioned UAE as a growth vector.

The bull-bear ledger

  • H1 revenue beat prior guidance (78.5% growth delivered vs. 70–80% guided)

  • Executable order book ₹384 Cr provides 2+ years of revenue visibility

  • Management disciplined ('no growth at any cost'); defending margin floor

  • Government tailwinds (PNG drive, renewable target, GOBARDHAN) are real and addressable

  • EBITDA margin fell 193 bps and PAT margin fell 202 bps YoY despite 78.5% growth

  • CGD remains 66% of revenue; early-stage ventures (solar, power, biogas) are unprofitable or nascent

  • Working capital drag acknowledged but 45–60 day conversion target may be optimistic for infrastructure projects

  • FY30 ₹1,000 Cr target lacks concrete operating mechanism (capex plan, acquisition strategy, new verticals)

  • UAE expansion deferred indefinitely due to geopolitical risk

Risks ranked by severity (holder's perspective)

Key execution and financial risks

Margin compression persists into H2 and FY28

High

EBITDA margin -193 bps and PAT margin -202 bps YoY despite 78.5% growth signals operational leverage is negative, not positive. If this repeats in H2, the FY27 guidance of ₹190–200 Cr profit could miss sharply. Reprice downward.

CGD segment concentration and execution risk (66% of H1 revenue)

High

City gas distribution is still the profit engine but margins are compressing (blended ~20% vs. prior 24%+). Order intake depends on government infrastructure cycles; delays or scope reductions could clip top-line and profitability.

Working capital drag; 45–60 day conversion may slip

Medium

Infrastructure projects are inherently cash-intensive; government certification and payment delays are endemic. Current assets are swollen. If conversion stretches to 90+ days, operating cash flow will lag reported profit by quarters, starving the balance sheet and forcing new borrowing at unattractive rates.

New ventures (compressed biogas, solar EPC, power) unproven at scale; early losses

Medium

Biogas posted H1 loss of ₹5.09 lakh; solar and power are nascent. If these ramp slower than expected or at margins lower than guided (10–12%), the company cannot meet its 2–3 year diversification targets. Execution delay on any venture extends CFD-heavy dependency.

UAE Desco Global FZ-LLC deferred; international growth thesis on hold

Medium

Geopolitical tensions in Middle East have halted UAE expansion. Company hopes to open price bid within 2–3 months but no firm timeline. International growth is off the table for 12+ months; FY30 ₹1,000 Cr ambition becomes harder to achieve with domestic-only footprint.

FY30 ₹1,000 Cr target lacks concrete operating plan

Medium

Company has articulated an ambitious 10x revenue target but provided no detail on how to achieve it (capex roadmap, acquisition pipeline, new sector entry, or international scale). Without a credible mechanism, the target is aspirational, not strategic. Repeated guidance misses could destroy credibility.

How the street is positioned

The market has already rendered its verdict. Desco's stock sits at ₹167.8 as of 6 November 2026, having shed 42.86% from its all-time high of ₹293.65. It now trades below its 20-day moving average (₹173.91), 50-day average (₹174.51), and 200-day average (₹186.18) — a sustained bearish technical posture. The RSI of 43.7 is neutral to slightly oversold, but the trend is downward.

More telling is the institutional positioning. Foreign institutional investors (FII) have exited entirely, falling from 5.09% of ownership in Q4 FY2025 to 0.00% as of Q4 FY2026. Domestic institutional investors (DII) have also trimmed, losing 1.02 percentage points quarter-on-quarter. Promoter holding has risen slightly to 58.31%, a sign that only the promoters are adding at these prices. Volume is increasing, which typically signals continued selling pressure rather than accumulation.

The market's message is clear: margin compression and unproven new ventures are enough to justify a 42% drawdown from highs, and the ongoing volume trend suggests capitulation has not yet exhausted itself. This contradicts any thesis that the ₹384 Cr order book alone justifies a re-rating. The market is pricing in execution risk, not order book visibility.

What to watch next

Three concrete data points that resolve the debate
  • 1 · Q3 EBITDA margin trend

    Did the 193 bps margin compression stabilize in Q3, or is it widening further? This is the most material variable. A stable margin (flat to -50 bps YoY) would suggest the company has crossed the mix/execution trough. Continued erosion (>150 bps) would signal structural challenges and risk further downside.

  • 2 · Compressed biogas commercialization (pre-Diwali 2026)

    Management expects injection into the Adani Total Gas pipeline before Diwali (late Nov / early Dec 2026). If this milestone is missed or delayed, the company loses a near-term catalyst and investors will further discount new venture execution risk.

  • 3 · Working capital cash conversion (target: 45–60 days)

    Is the company collecting on its swollen current assets as promised? If Q3 operating cash flow outpaces reported profit, the working capital story resolves positively. If it lags, the company is burning cash and may need to raise capital at an unfavorable price.

  • 4 · Loan refinancing close (target: Dec 15, 2026)

    The company aims to refinance ₹150 Cr in NBFC loans (currently at 16–17%) to lower rates by mid-December. If this closes on schedule and at materially lower rates, it reduces interest drag and supports FY28 profitability.

  • 5 · H2 execution delivery (₹115–125 Cr revenue required to meet FY27 guidance)

    H2 (Oct–Mar) is always concentrated for infrastructure; company guided that H2 must deliver ₹115–125 Cr to meet full-year ₹190–200 Cr guidance. If Q3 and Q4 come in below this band, the company misses its own guidance and loses credibility.

The honest close

Desco Infratech is executing, not failing. H1 revenue of ₹75 Cr beat prior expectations. The ₹384 Cr order book is real and provides material visibility. Management is appropriately cautious and focused on cash conversion, not growth-at-any-cost. But profit quality has deteriorated measurably — margins are compressing at the moment the company should be gaining leverage. The company is signaling that normalized long-term margins will be 15–20%, not 21%+. That is a repricing of the franchise.

The market has already done that repricing, marking the stock down 42.86% from highs. FII have fled. Promoters are the only buyer. The question is whether the current price of ₹167.8 reflects fair value or oversold technicals. Given the unresolved margin trajectory and execution complexity ahead, the prudent stance is to wait for proof — specifically, a Q3 margin print that shows stabilization and a working capital conversion that validates management's 45–60 day promise.

Rating: Hold. The order book supports the FY27 guidance, and no imminent financial distress is evident. But the profit quality deterioration and FY30 ambition's lack of a concrete operating plan argue against initiation or accumulation. Margin stabilization and cash conversion are the gates. If both clear in Q3, the stock may re-rate higher. If either fails, the market will re-test lower. For now, track the EBITDA margin from quarter to quarter — that single number will determine whether Desco is a recovery play or a value trap.

Informational and educational content only. Not investment advice.